"New kid on the block"-MDDM as a new ingredient in Ecstasy tablets.
Bogumiła Byrska, Karolina Masier, Roman Stanaszek
Journal of Forensic Sciences November 18, 2025 DOI: 10.1111/1556-4029.70226 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Sample size | 150 |
| Population | Ecstasy tablets seized in Poland between 2020 and 2021 |
| Topics | MDMA |
| Keywords | Mddm New psychoactive substances Novel compound Synthesis by-product Designer drug Nps Mda Illicit drugs Street drugs Club drugs Amphetamines Forensic drug analysis Chemical profiling Substance identification Drug chemistry Forensic science Illicit drug analysis Drug toxicity Public health concern Harm reduction Drug safety Adverse effects Overdose risk Health implications |
| Key findings | Ecstasy tablets contained MDMA, MDA, and the novel phenylethylamine derivative MDDM, with MDA in the highest concentrations, raising concerns about unpredictable composition and potential synergistic toxicity. |
Abstract
Ecstasy tablets are commonly associated with 3,4-methylenedioxy-methamphetamine (MDMA), but they often contain diverse psychoactive substances, including new psychoactive substances (NPS), which pose significant risks to users due to unknown composition and effects. This study analyzed 150 Ecstasy tablets seized in Poland between 2020 and 2021, shaped as "Stormtrooper" heads, to identify their chemical composition. Using gas chromatography-mass spectrometry (GC-MS) and ultra-high-performance liquid chromatography with photodiode array detection (UHPLC-PDA), we detected MDMA, 3,4-methylenedioxyamphetamine (MDA), and for the first time in Polish seizures, a novel phenylethylamine derivative-3,4-methylenedioxy-N,N-dimethylamphetamine (MDDM). MDDM, a methyl analogue of MDMA and dimethyl analogue of MDA, has limited pharmacological data and reportedly mild psychoactive effects. Its presence is likely linked to impurities or by-products formed during illicit MDMA synthesis. Quantitative analysis revealed that MDA occurred in the highest concentrations per tablet (26-74 mg), followed by MDDM (11-28 mg) and MDMA (3-11 mg). Although MDDM alone is considered to have low potency, its co-occurrence with other phenylethylamines may produce synergistic effects, potentially increasing toxicity. These findings shed light on synthetic routes in illicit MDMA production and highlight the unpredictable chemical composition of street drugs. The detection of multiple active substances-even at low doses-raises significant public health concerns, highlighting the necessity for continuous forensic monitoring and increased awareness of the dynamic and complex nature of synthetic drug markets.
Comparable studies
Other observational and cohort studies on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Subjective Reports of the Effects of MDMA in a Clinical Setting Individuals who took MDMA in a clinical setting | 1986 | Observational study | |
| Memory impairment in abstinent MDMA ("Ecstasy") users Abstinent MDMA users | 1998 | Observational cohort | |
| Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people | 2000 | Observational | |
| The Psychological and Physiological Effects of MDMA on Normal Volunteers Older, more educated, drug-experienced individuals | 1986 | Observational cohort | |
| Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits Young people who were regular or novice MDMA users, or non-users | 1998 | Observational cohort | n = 30 |